Decomposable STING nanoagonist-amplified oncolytic virotherapy through remodeling the immunosuppressive microenvironment of triple-negative breast cancer

T cells and maturation dendritic cells (DCs) due to the synergetic effect of the STING pathway and OVs, thereby activating the immune response, resulting in the significant inhibition of TNBC growth. This work highlights the potential of the STING agonist in enhancing the antitumor efficacy of OVs and provides a potent platform for TNBC therapy.